Onglisa: ogwu maka oria shuga, nyocha na analogues nke mbadamba

Peeji a na-enye ndepụta nke analogues nke Ongliz niile site na ihe mejupụtara na ngosipụta maka ojiji. Ndepụta analogues dị ọnụ ala, ị nwekwara ike ịtụle ọnụ ahịa dị na ụlọ ahịa ọgwụ.

• Ananglaz dị ọnụ ala karịa:Trazenta
• Analog nke kacha ewu ewu nke Ongliz:Vipidia
• Nhazi ATX: Saxagliptin
• Ngwaọrụ mejupụtara / ihe mejupụtara: saxagliptin
  

Mgbe ị na-agbakọ ọnụ ego ahụ ọnụ ala analogues na-adịghị atụ nke Ongliz agbakwunyere ụgwọ opekata mpe enwere na ndepụta ọnụahịa nke ndị ahịa ọgwụ nyere

Nyere ndepụta ọgwụ analogues dabere na ndekọ ọnụ ọgụgụ nke ọgwụ a kacha chọọ

Analogs site na ngosipụta na usoro eji

Ngwakọta dị iche iche, nwere ike yikọ ọnụ na njiri na usoro nke ngwa

Etu esi achọta analog dị ọnụ ala nke ọgwụ na-akwụ ụgwọ?

Iji chọta analog dị ọnụ ala na ọgwụ, njiri mara ma ọ bụ ntụgharị, nke mbụ anyị na-atụ aro ị payinga ntị na ihe mejupụtara ahụ, ya bụ otu ihe ahụ na njiri mara maka ojiji Otu ihe eji eme ọgwụ eme ihe ga-egosi na ọgwụ ahụ kwekọrọ na ọgwụ ahụ, ọgwụ kwekọrọ ma ọ bụ ọgwụ ọzọ. Agbanyeghị, echefula maka ihe ndị na - adịghị ike nke ọgwụ ndị yiri ya, nke nwere ike imetụta nchekwa na ịdị irè. Echefula banyere ntuziaka nke ndị dọkịta, ọgwụ ịchọrọ onwe gị nwere ike imerụ ahụ ike gị, yabụ gbaa dọkịta gị mgbe niile tupu ị usingụ ọgwụ ọ bụla.

Ntụziaka Onglisa

INWETA
n'iji ọgwụ eme ihe
Onglisa

Mpempe mwepụta
Mbadamba ihe mkpuchi.

Ngwakọta
Saxagliptin 2,5 na 5 mg,
Ndị ọkachamara: lactose monohydrate, microcrystalline cellulose, ssumum croscarmellose, magnesium, 1 M hydrochloric acid ma ọ bụ sodium hydroxide 1 M, Opadray II ọcha (polyvinyl mmanya, titanium dioxide, macrogol (PEG 3350, talc), Opadray II odo (mmanya) polyvinyl, titanium dioxide, macrogol (PEG 3350), talc, iron dye odo oxide (E172)), ink Opacode acha anụnụ anụnụ (shellac na ethyl mmanya, FD&C Blue # 2 / indigo carmine aluminom pigmenti (E132), n-butyl mmanya, propylene glycol, mmanya isopropyl, 28% ammonium roksid).

Mbukota
Na ngwugwu nke mbadamba iri atọ.

Omume ọgwụ
ONGLISA - saxagliptin - nhọrọ nhọrọ siri ike na - emegharị onye nwere ike iweghachite dipeptidyl peptidase-4 (DPP-4).
N'ime ndị ọrịa nwere ụdị ọrịa shuga 2 nke mellitus, nchịkwa nke saxagliptin na-egbochi ọrụ nke enzyme DPP-4 maka awa 24. Mgbe ịba ụba glucose, mmachi nke DPP-4 na-eduga na mmụba okpukpu abụọ na glucagon-like peptide-1 (GLP-1) na glucose-based insulinotropic glucose. polypeptide (HIP), mbelata nke mkpokọta glucagon yana mmụba na nzaghachi glucose nke mkpụrụ ndụ beta, nke na-eduga n'ịbawanye ụba nke insulin na C-peptide.
Mwepụta nke insulin site na mkpụrụ ndụ beta nke pancreatic yana mbelata nke ịtọhapụ glucagon site na mkpụrụ ndụ alịcreatic na-eduga na mbelata nke glycemia na-ebu ọnụ na postprandial glycemia.
A mụrụ ịdị ike na nchekwa nke saxagliptin mgbe ewere ya na usoro mg 2,5, 5 mg na 10 mg 1 oge / a mụrụ n'ọmụmụ abụọ kpuru ìsì abụọ, na-achịkwa placebo na ndị ọrịa 4148 nwere ụdị ọrịa 2.Tụ ọgwụ ahụ nwere nnukwu mmụba dị ukwuu na ọbara glycosylated hemoglobin (HbA1c), glucose plasma glucose (GPN) na plasma glucose postprandial (PPG) ma e jiri ya tụnyere njikwa.
Ndị ọrịa a na-ejikọghị akara nke glycemic na saxagliptin dị ka monotherapy edekwara metformin, glibenclamide ma ọ bụ thiazolidinediones. Mgbe ị na-ewere saxagliptin na 5 mg, a hụrụ nbelata HbA1c mgbe izu anọ na GPN gasịrị izu abụọ. N'ime ìgwè ndị ọrịa na-anata saxagliptin na metformin, glibenclamide ma ọ bụ thiazolidinediones, a hụrụ nbelata HbA1c mgbe izu anọ na GPN gasịrị izu abụọ.
Mmetụta saxagliptin na profaịlụ nke egbugbere ọnụ yiri nke placebo. N'oge ọgwụgwọ saxagliptin, ọ nweghị mmụba dị arọ n'ahụ ama ama ama.

Onglisa, ihe ngosi iji
Elldị shuga mellitus 2 na mgbakwunye na nri na mmega iji melite njikwa glycemic na ogo:
- monotherapy,
- na - amalite usoro ọgwụgwọ na metformin,
- agbakwunye na monotherapy nwere metformin, thiazolidinediones, usoro nke sulfonylurea, na enweghị enweghị nchịkwa glycemic zuru oke na usoro ọgwụgwọ a.

Ihe ngbanwe
- ụdị shuga mellitus nke 1 (adịghị amụ amụ),
- iji insulin eme ihe (adighi amu ya),
- ọrịa mamịrị ketoacidosis,
- enweghi nsogbu galactose, ụkọ lactase na glucose-galactose malabsorption,
- afọ ime
- lactation,
- gbara afọ 18 (amụọbeghị nchekwa na arụmọrụ),
- mụbaa ọgụgụ isi onye ọ bụla na ọgwụ ahụ.

Usoro onunu ogwu na nhazi
Edere ọgwụ a n'ọnụ, n'agbanyeghị nri ị ga-eri.
Na monotherapy, ọgwụ a tụrụ aro nke saxagliptin bụ 5 mg 1 oge / ụbọchị.
Na njikọta ọgwụ, ọgwụ a tụrụ aro nke saxagliptin bụ 5 mg 1 oge / ụbọchị yana mgbakwunye na metformin, thiazolidinediones ma ọ bụ sulfonylureas.
Mgbe ịmalite usoro ọgwụgwọ na metformin, usoro a tụrụ aro ya maka saxagliptin bụ 5 mg 1 oge / ụbọchị, usoro mbụ nke metformin bụ 500 mg / ụbọchị. N'ihe banyere nzaghachi ezughị ezu, enwere ike ịbawanye dose nke metformin.
Ọ bụrụ n ’ịwụlị were Ongliz®, ị kwesịrị iburu mbadamba ihe echefuru ozugbo onye ọrịa chetara nke a, mana ịhapụ ị notụ ọgwụ okpukpu abụọ nke otu ụbọchị.
Maka ndị ọrịa nwere ezughi oke gbasara akụrụ (CC> 50 ml / min), a chọghị ndozi dose. Maka ndị ọrịa nwere obere akwara oke ma ọ bụ daa ada (CC ≤50 ml / min), yana maka ndị ọrịa na hemodialysis, ọgwụ akwadoro nke Ongliz® bụ 2.5 mg 1 oge / ụbọchị. Ekwesịrị ị drugụ ọgwụ ahụ na njedebe nke nnọkọ hemodialysis. Amabeghị ojiji nke saxagliptin na ndị ọrịa na-ele mgbaaka peritoneal dialysis. Tupu ịmalite ọgwụgwọ na saxagliptin na n'oge ọgwụgwọ, a na-atụ aro ka ị nyochaa ọrụ akụrụ.
Ọ bụrụ na arụ ọrụ akpịrị na-adịghị arụ ọrụ, ọ dịghị mkpa idozigharị ọnya dị nro, na-agafe agafe na nke siri ike.
Ọchọghị ime mgbanwe na ndị ọrịa agadi. Agbanyeghị, mgbe ị na-ahọrọ ọgwụ, ekwesịrị iburu n'uche na n'ụdị ndị ọrịa a, mbelata ọrụ ọrụ akụrụ nwere ike ịdị.
A mụbeghị nchekwa na ịdị mma nke ọgwụ ahụ na ndị ọrịa na-erubeghị afọ 18.
Mgbe ejiri ikike CYP 3A4 / 5 dị ike, dịka ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir na telithromycin, ọgwụ a tụrụ aro Ongliz® bụ 2.5 mg 1 oge / ụbọchị

Ime na lactation
N'ihi eziokwu ahụ bụ na ojiji nke saxagliptin n'oge ime, agụghị ọgwụ a n'oge a.
Amaghi ma saxagliptin banye na mmiri ara.N'ihi eziokwu ahụ bụ na a gaghị ewepụ ohere nke ịbanye saxagliptin n'ime mmiri ara, a ga-akwụsị inye nwa ara maka oge ọgwụgwọ ya na saxagliptin ma ọ bụ usoro ọgwụgwọ, na-eburu n'uche ihe ize ndụ nwatakịrị ahụ na abamuru nke nne ya.

Nsonaazụ
Ọkpụkpụ akụkụ akụkụ okuku ume na-efe efe
Ọrịa ọnya na-efe efe
Ọrịa mamịrị
Ọrịa Sinusitis
Vomiting
Isi ọwụwa.

Ntụziaka pụrụ iche
Agụbeghị ọgwụ Onglisa® nke ọgwụ yana insulin, yana na usoro ọgwụgwọ atọ na usoro metformin na thiazolidinediones ma ọ bụ usoro metformin na sulfonylurea.
Ndị ọrịa nwere ọrụ mgbazinye nsogbu.
A na-atụ aro idozi dose maka ndị ọrịa nwere obere akwara oke, yana maka ndị ọrịa na hemodialysis. Tupu ịmalite ọgwụgwọ na oge ụfọdụ n'oge ịgwọ ọgwụ ahụ, a na-atụ aro iji nyochaa ọrụ gbasara akụrụ.
Jiri yana ọgwụ ndị nwere ike ibute hypoglycemia.
Ihe dị iche iche nke sulfonylureas nwere ike ibute hypoglycemia, yabụ, iji belata ihe ize ndụ nke hypoglycemia mgbe ị na-eji Ongliz®, enwere ike ịbelata dose nke sulfonylureas.
Mmeghachi omume hypersensitivity.
Ekwesighi inye ndi oria ndi nwetagoro nnabata ahuhu ọgwụ ogwu ahu mgbe ha ji ndi ozo ha dochie DPP-4.
Ndị okenye na-arịa ọrịa.
Dika ihe omumu banyere ogwu, odi nma na ihe ndi n’egosiputa nchekwa n’ime ndi oria n’agburu n’afo iri-isii n’obe karighi ihe egosiputara ya n’ebe ndi oria di. Agbanyeghị, mmụba nke mmadụ na-arịwanye elu nke zirigliptin n'ụfọdụ ndị ọrịa agadi agaghị enwe ike chịa.
Saxagliptin na metabolite ya bụ akụkụ akụrụ akụkụ ụfọdụ, yabụ, a ga-eburu n'uche na ndị ọrịa merela agadi, ọ nwere ike nwee mbelata ọrụ obere akụrụ. Onglisa® nwere lactose. Ndị ọrịa nwere ọrịa galactose ekweghị ibe nọrọ, ụkọ lactase na glucose-galactose malabsorption ekwesịghị ị thisụ ọgwụ a.

Mmetụta ikike ịkwọ ụgbọ ala na usoro nchịkwa.
Emebeghị nnyocha banyere mmetụta saxagliptin na ikike ịkwọ ụgbọala na usoro nchịkwa. Buru n’uche na saxagliptin nwere ike ibute ọgbụgba.

Mkparịta ụka ọgwụ ọjọọ
Nnyocha nyocha data nyocha ụlọ ọgwụ na-egosi na ihe ọghọm nke mmekọrịta mmekọrịta dị oke egwu nke saxagliptin na ọgwụ ndị ọzọ mgbe ejikọtara ọnụ dị obere.
Saxagliptin metabolism bụ sistemụ cytochrome P450 3A4 / 5 na-anọpụ iche (CYP3A4 / 5) na-eme ka onye mgbasa ozi dị ukwuu. Na nyocha nke vitro egosila na saxagliptin na metabolite ya bụ isi anaghị egbochi CYP 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1 na 3A4 isoenzymes ma ghara ịbanye CYP 1A2, 2B6, 2C9, na 3A4 isoenzymes. N'ime ọmụmụ metụtara ndị ọrụ afọ ofufo siri ike, ọgwụ pharmacokinetic nke saxagliptin na metabolite ya agbanweghị nke ukwuu n'okpuru metformin, glibenclamide, pioglitazone, digoxin, simvastatin, diltiazem, ketoconazole, omeprazole, ngwakọta nke hydroxide aluminom, magnesium hydroxide, Saxagliptin anaghị agbanwe oke ọgwụ pharmacokinetic nke metformin, glibenclamide, pioglitazone, digoxin, simvastatin, diltiazem ma ọ bụ ketoconazole.
Emebeghị ka mmetụta nke inducers nke CYP 3A4 / 5 isoenzymes na pharmacokinetics nke saxagliptin. Agbanyeghị, ojiji jikọtara saxagliptin na ntinye nke CYP 3A4 / 5 isoenzymes, dị ka carbamazepine, dexamethasone, phenobarbital, phenytoin na rifampicin, nwere ike ibute mbelata nke saxagliptin na plasma na mmụba na mkpokọta nke metabolic isi ya.A mụbeghị ihe ọmụmụ banyere ị ofụ sịga, ihe oriri, nri ọgwụ, yana iji mmanya egbu nri na saxagliptin.

Dodoụbiga ya ókè
Achọpụtaghị ọrịa nke mmanya egbu yana iji ọgwụ ogologo oge na usoro onunu ogwu ruo ugboro iri asatọ karịa ka akwadoro.
Ọgwụgwọ: a bụrụ na ị doụbiga ya ókè, ekwesịrị iji usoro ọgwụgwọ Symptomatic mee ihe. Saxagliptin na metabolite ya bụ isi sitere na hemodialysis wepụta ya (etu esi eme ya: 23% nke dose ahụ n'ime awa anọ).

Ọnọdụ nchekwa
Mgbe okpomọkụ agaghị adị 30 Celsius

Onglisa: ntuziaka maka ojiji, nyocha, ole

Site na ntoputa nke ụdị ọrịa shuga 2, endocrinologist ga-ahọrọ ọgwụ kwesịrị ekwesị. Ha na-ahapụ gị ka ịzie ịdị omimi nke glucose na ọbara. Otu n'ime ngwaọrụ ndị a bụ Onglisa. Tupu ịzụta, ọ bụ ihe amamihe dị na ya maka ndị ọrịa ịchọpụta ozi dị mkpa gbasara ọgwụ a. Ntụziaka maka iji Onglises, analogues, reviews na price - ndị ọrịa mamịrị kwesịrị inwe mmasị n'ihe niile.

Ngwakọta nke ngwaahịa na ụdị ntọhapụ

Akụkụ bụ isi nke Onglisa bụ saxagliptin hydrochloride. Nke a bụ ọgwụ hypoglycemic: dipeptidyl peptidase-4 inhibitor (DPP-4).

Ngwaahịa a dị n’ụdị mbadamba ụrọ, ndị nwere ihe mkpuchi na fim. Na irere ahia i nwere ike ihu “Onglizu” site na iji udiri ogwu eme ihe 2.5 na 5 mg. Mbadamba mbadamba ihe ndị ahụ na blisters, ha na-ere ere na paịlị: nke ọ bụla nwere 3 blisters.

A maara ọgwụ ahụ n'okpuru INN (aha mba ụwa na-akwadoghị) saxagliptin.

Mmetụta ọgwụ

Mgbe ị na-ewere hypoglycemic a, a na-ebelata ọrụ enzyme DDP-4 n'ime awa 24. Mgbe ị na-a gluụ glucose, mgbanye nke GLP-1 na GUI na-abawanye site na ugboro 2-3. N'otu oge ahụ, ọkwa glucagon na-ebelata, nzaghachi glucose na mkpụrụ ndụ beta na-abawanye. N'ihi usoro nke usoro ndị a, ịta C-peptide na insulin na-abawanye.

Mgbe ewepụtara insulin na pancreas (mkpụrụ ndụ beta ya pụrụ iche), na-ebelata usoro glucagon wepụtara na mkpụrụ ndụ alfa, enwere mbelata na glycemia na-ebu ọnụ mgbe erichara nri.

A nwalere nchekwa na arụmọrụ nke saxagliptin n'ime ọmụmụ 6 na-achịkwa njeche n'ime ndị ọrịa nwere ụdị shuga 2. N'ụzọ pụtara ìhè, achọpụtara ya na haemoglobin glycins, shuga ọbara na-ebu ọnụ ma mgbe ị risịrị nri mgbe niile ka mma.

Saxaliptin mgbe nchịkwa na-etinye obi gị dum na eriri afọ, a na-ahụkarị ntinye uche mgbe awa 2 (isi metabolite - 4) gasịrị. A na-etinye ihe karịrị 75% nke ọgwụ a na-etinye. A na - ewepụ ihe dị n'ọrụ dị na bile na mmamịrị.

Ndepụta nke egosi

Enwere ike ịkọwa ngwá ọrụ "Onglisa" maka ọrịa shuga, nke mepụtara dabere na ụdị 2. Edere ọgwụ a ka ihe jikọrọ njikwa glycemic mgbe ị na-eri nri na mmega ahụ.

Denye mbadamba nkume ndị a:

• ka uzo eji emechi aru,
• dị ka mgbakwunye maka monotherapy nwere usoro sulfonylurea, metformin, thiazolidinediones,
• maka ịmalite ọgwụgwọ ọgwụgwọ na ngwakọta na metformin.

Amachibidoro ịmalite ị theụ ọgwụ ahụ n'onwe gị n'enyeghị ọgwụ dọkịta.

A na - eji “Onglizu” eme ihe dị ka ọgwụ ndị ọzọ yana ọgwụ ndị ọzọ na - agbakọta, ma ọ bụrụ na monotherapy na-ebelata ọgwụ shuga enweghị ike inweta nchịkwa glycemic zuru oke.

Nhọrọ onunu ogwu, usoro eji

Onye na-ahụ maka endocrinologist kwesịrị ịkọpụta usoro onunu ogwu, na-eburu n'uche ọnọdụ onye ọrịa.

Site na monotherapy "Onglise", a na-eme nhọrọ kacha mma maka mbadamba 5 mg. A na-ewere ha otu ụbọchị kwa ụbọchị.

Mgbe ị na-eji usoro ọgwụgwọ ọgwụ ndị a jikọtara ọnụ mee ihe, a na-atụ aro ka ọ were saxagliptin na ego nke 5 mg na ngwakọta sulfonylurea, ọgwụ thiazolidinedione, metformin.

N'inwe mkpebi ịmalite usoro ọgwụgwọ ejikọtara na metformin na saxagliptin, ọ dị mkpa ịhọrọ ọgwụ ndị ahụ ka ihe mbụ nọ n'ọrụ na-abanye ahụ ahụ na 500 mg, nke abụọ - 5 mg kwa ụbọchị. Na enweghị nzaghachi zuru oke, mụbaa dose nke metformin.

Ọ bụrụ na apụtaghị ihe dị na mbadamba ụrọ nke Ongliza, ị ga-a drinkụ ya ozugbo, ozugbo onye ọrịa mamịrị chetara ya. Mana ị nweghị ike ị tabletsụ mbadamba 2 kwa ụbọchị.

Usoro ọgwụgwọ maka ndị ọrịa ọrịa shuga na-agbagha site n'ọrịa concomitant na-ahọpụta iche:

• ya na akuko gbasara adi, ogha adi ya,
• site na iji obere akwara na-ada ada, "Ongliza" ka etinyere 2.5 mg (otu mbadamba nkume ahụ ka akwadoro maka ndị ọrịa na hemodialysis),
• dysfunction of imeju achọghị mmezi dose,
• na ndị ọrịa agadi nwere ọrụ akụrụ dị mma, a na-edenye ọgwụ ahụ na usoro onunu ogwu.

Tupu ị medicationsụọ ọgwụ ndị e mere na ndabere nke saxagliptin, ịkwesịrị ịlele akụrụ, nyochaa ọrụ ha.

Ihe ngbanwe

Tupu ịkọwa Onglisa, dọkịta kwesịrị ịmata akụkọ banyere ahụike nke onye ọrịa ahụ wee chọpụta ma ọ nwere ike ị drinkụ ọgwụ a.

Ndepụta contraindications gụnyere ihe ndị a:

• ike nwere mmetụta n'akụkụ ngwaahịa niile,
• galactose anabataghị, ọrịa glucose-galactose malabsorption ma ọ bụ ụkọ lactase,
• ọrịa mamịrị ketoacidosis,
• oge ime na inye nwa ara.

Edeghị ọgwụ a maka ndị ọrịa nwere ụdị shuga na-akpata insulin na ndị ọrịa ahụ na-eji insulin maka ọgwụgwọ ọbụlagodi T2DM. N'ọnọdụ ndị a, amụtaghị ojiji nke saxagliptin.

Maka otu ihe ahụ, a naghị akwado ya ka ịdebe mbadamba nkume ndị a maka ụmụaka.

Na njikọta nke usoro mmanụ sulfonylurea, a na-eji ogwu akpachara anya.

Ọzọkwa, a ga-enyocha ọnọdụ ahụ site n'aka ndị ọrịa nwere ọdịda akụrụngwa (na-enwe ọfụma na ụdị siri ike), ndị agadi.

Amabeghị iji ọgwụ n’oge afọ ime. Amabeghị ma ọgwụ a na-abanye na mmiri ara. Ya mere, n'oge ọgwụgwọ, ndị dọkịta na-atụ aro ịkwụsị nri ma ọ bụ jụ ọgwụgwọ na saxagliptin.

Omume mmetụta enwere ike

Patientsfọdụ ndị ọrịa na-etolite ọrịa ma ha na-ewere Onglisa.

Enwere ezigbo ihe egwu mgbe ha mere? Ọ bụrụ na onye ọrịa ahụ achọpụtala nsonaazụ ọ bụla, mgbe ahụ, a ga-achọ ndụmọdụ onye dọkịta ka o nyochaa ọnọdụ ahụ wee chọpụta ike ọgwụgwọ a.

Agbanyeghi na usoro nyocha, a haziri ihe ndia. Ọnọdụ nke ihe ọghọm dị na isiokwu na-ewere saxogliptin bụ etu ọghọm dị na ndị ọrịa nwụrụ.

N'otu oge ahụ, enweghị nnukwu ọdịiche dị n'etiti ị theụ ọgwụ ahụ n'ụdị monotherapy yana yana ọgwụgwọ njikọta.

Enwere ike ịdaba na nsogbu ndị dị otu ahụ:

• akụkụ okuku ume na akụkụ nke akụkụ elu (akụkụ elu),
• urinary tract na-efe efe
• sinusitis
• eriri afọ
• vomiting
• isi ọwụwa.

Nnyocha ndị ahụ chọpụtara na izu nke iri abụọ na anọ nke ọgwụgwọ, ụfọdụ ndị ọrịa nọgidere na-enwe mmeghachi omume mmetụta uche: 1.5% ndị mmadụ na-ewere Onglizu na 0.4% nke ndị mmadụ na-ewere placebo. Mana mmeghachi omume hypers na-ebilite n'oge nyocha ahụ enweghị ihe egwu nye ndụ ndị ọrịa ma ọ chọghị ọgwụgwọ.

Site na usoro ọgwụgwọ ọgwụgwọ, achọpụtara ihe ndị a.

Ojiji saxagliptin na glibenclamide butere hypoglycemia na 0.8% nke ikpe, na otu njikwa (na-ewere placebo) - na 0.7%. Ọnọdụ nke hypoglycemia na ojiji nke metformin na thiazolidinedion na-emekọ ihe ọnụ yana ọnọdụ nke hypoglycemia na ndị ọrịa e nyere placebo.

Site na njikọta nke saxagliptin na thiazolidinediones, akụkụ ụsọ ụkwụ bịara na 8.1% nke ikpe, na otu njikwa - 4,3%.Mana ọzịza ya rụpụtara bụ nwayọ ma ọ bụ agafeghị oke, nkwụghachi ọgwụgwọ adịghị mkpa. Site na monotherapy na njikọ ndị ọzọ, nsogbu a mere na 1.7%, ebe ị na-ewere placebo na 2.4%.

Ojiji nke Onglisa na ọgwụ metformin nwere ike ibute nasopharyngitis na isi ọwụwa. Nasopharyngitis mere na 6.9% nke ndị ọrịa: ya na metformin monotherapy - 4%, saxagliptin - na 4.2% nke ndị ọrịa. 7.5% mere mkpesa banyere isi ọwụwa: ya na metformin monotherapy - 5.2%, saxagliptin - 6.3% nke ndị ọrịa.

Enweghi mgbanwe mgbanwe pụtara na palọm n'ụlọ nyocha ahụ n'oge ọmụmụ nke saxagliptin. E nwere obere mbelata na lymphocytes enwere ike, mana ọnụ ọgụgụ ha ka nọgidere na ọkwa kwụsiri ike.

Casesụbiga okwu ókè

Ndị na-emepụta ọgwụ na ọgwụ ziri ezi saxagliptin, gụnyere Onglises, anaghị atụ aro iri mbadamba ọgwụ abụọ n'ime otu ụbọchị ahụ mgbe ị na-egwu ọgwụ ọzọ. Ma mgbe ị theụ ọgwụ ahụ ogologo oge na usoro onunu ogwu karịa ihe a tụrụ aro ruo ugboro iri asatọ, ahụghị ihe mgbaàmà nke ịxụ mmanya.

Mana ntuziaka maka ojiji na-ekwu na ị anụbiga ọgwụ ike ókè, a ga-ewepụ ọgwụ ahụ site na hemodialysis. Ruo awa anọ, ọgwụ 23% dị na ọgwụ ahụ.

Mkparịta ụka ọgwụ ọjọọ

Mgbe ndị dọkịta na-ede Onglisa, ndị dọkịta anaghị enwekarị mmasị na ụdị ọgwụ ị ka na-eji. E kwuwerị, ihe ize ndụ nke mmekọrịta dị n'etiti ọgwụ a na ọgwụ ndị ọzọ dị obere.

Ntinye uche nke metabolite nke saxagliptin nwere ike ibelata mgbe ị na-eji ntanetị nke CYP 3A4 / 5 icheenzymes (dịka Phenobarbital, Carbamazepine, Phenytoin, Dexamethasone, Rifampicin).

Mgbe ejikọtara ya na usoro nke sulfonylurea, akpachara anya kwesịrị ịkpachara anya: hypoglycemia nwere ike ịmalite. Can nwere ike belata ihe ize ndụ site na ibelata dose nke nkwadebe sulfonylurea.

Ntụziaka pụrụ iche

Nnyocha nke otu “Ongliza” si emetụta ikike iji ụgbọ ala na ihe ọgbụgba arụ ọrụ. Amabeghị etu ị alcoholụ mmanya, ị alcoholụ sịga, na iji ọgwụ agwọ ọrịa si emetụta.

Ọ bụrụ na ndị ọrịa enweburu mmeghachi omume mmụọ mgbe ha na-eji ndị na-egbochi D1111-4, mgbe ahụ, ekwenyeghị Ongliz.

Iwu ọnụahịa na nhọrọ nke analogues

You nwere ike ịzụta ọgwụ ahụ n'ọtụtụ ahịa ọgwụ. Mana ọnụahịa ya dị elu: maka ngwugwu nke mbadamba 30 nke 5 mg, 1881 rubles kwesịrị inye. Agaghị etinye ọgwụ a na ndepụta ọgwụ ọgwụ preferensị nke enwere ike inye onye ọrịa nwere ụdị shuga 2 site na ndenye ọgwụ n'efu.

Ndị ọrịa nwere ikike ịrịọ endocrinologist maka ọgwụ maka inye ha ọgwụ ọzọ ga - eji dochie Onglisa. Ọzọkwa, ndochi dị mkpa ma ọ bụrụ na onye ọrịa ahụ anabataghị ọgwụ nke saxagliptin.

Analogues gụnyere ọgwụ ndị dị belata shuga:

• "Galvus" - vildagliptin nọ n'ọrụ,
• "Januvia" - sitagliptin,
• "Vipidia" - alogliptin,
• "Trazhenta" - linagliptin,
• "Glucovans" - glibenclamide, metformin hydrochloride,
• Glucophage bụ Metformin hydrochloride.

Mana naanị endocrinologist kwesịrị ịhọrọ analogues nke ọgwụ “Onglisa” maka ọrịa shuga.

N'ime aha analorọ akọwapụtara akọwapụtara enweghị ọgwụ ọ bụla, na ikike nke Ministri Ahụike, enwere ike ịnye ha n'efu. Enweghi ike ịkpọ ọnụ ọnụ nke analogues ndị a dị ala.

Maka otu mkpọ 28 mbadamba 50 nke 50 nke Galvus, ịkwesịrị ịkwụ 810 rubles.

"Januvia" ga-akwụ ndị ọrịa 1650 rubles. - 28 taabụ. 100 mg ọ bụla.

“Vipidia” n’ụlọ ahịa ọgwụ na-akwụ 1288 rubles. - 28 taabụ. 25 mg ọ bụla.

"Trazhenta" na-efu 1785 rubles. - 30 mbadamba 5 mg ọ bụla.

Mana ọgwụ metformin dị ọnụ ala. Glucophage na-akwụ 114 rubles. (30 p. 500 mg nke ọ bụla), "Glucovans" 277 rubles. 30 taabụ. 500 / 2.5 mg nke metformin na glibenclamide, otu isi.

Nyocha nyocha Ndidi

Tupu inweta ọgwụ dị oke ọnụ dị otú a, ọtụtụ chọrọ ịmata etu ọ si arụ ọrụ yana ma ọ na-enyere ndị ọrịa ndị ọzọ aka.Ma uche nke ndị ọrịa mamịrị iji wee gwọọ ọrịa agwọagliptin abụghị otu: maka ụfọdụ ndị ọrịa ọgwụgwọ a na-aghọzi panacea, ebe ndị ọzọ na-eme mkpesa maka arụ ọrụ ya.

Mana nyocha ndị ọrịa na-enye ohere iji mee ihe banyere ọgwụ. Agbanyeghị echiche nke ndị ọzọ, ndị ọrịa mamịrị ga-abụ ndị ndụmọdụ nke usoro ọgwụgwọ endocrinologist na-eduzi. Ọ bụrụ na ha atụkwasịghị ya obi, mgbe ahụ ọ bara uru ịnwa ịgbanwe dọkịta.

Patientsfọdụ ndị ọrịa na-eme mkpesa na Onglisa anaghị arụpụta ihe a tụrụ anya ya. Somefọdụ, mgbanye glucose na-abawanye mgbe ị na-a theụ ọgwụ. Ndị dọkịta na-edepụta ọtụtụ “Ongliz” dị ka ụzọ mgbakwunye ọgwụgwọ ọzọ na ọgwụgwọ “Siofor”, “Diabeton”.

Ma ọtụtụ ndị ọrịa mamịrị, ọbụlagodi monotherapy nwere saxagliptin, jikwaa ị nweta nsonaazụ mara mma ma jikwaa glycemia. Uru nke ọgwụ a, ọtụtụ na-ekwu na ikike ị pụ ọgwụ n’oge ọ bụla, n’agbanyeghi nri nri.

Fọdụ na-ahụtakwa na ngwakọta na metformin na-enye ohere ịmara ọnọdụ ahụ. Mana iji mezuo nsonaazụ ịchọrọ, achọrọ ọgwụgwọ ogologo oge. Nke a bụ ihe na-atọ ọtụtụ ndị ụtọ. Site na usoro ọkọlọtọ, mbadamba ihe zuru ezu otu ọnwa.

Mana imirikiti ndị ọrịa ga-a drugsụ ọgwụ ndị ọzọ iji belata ihe ọrịa shuga na-arụ n’arụ na sistem ahụ.
Ọ bụrụ na dọkịta depụtara "Ongliza", mgbe ahụ ị ga-anwale ọgwụgwọ na ọgwụ a. Isi ihe ị ga-echeta banyere mkpa ị na-eso maka nri na mmejuputa mmega ahụ.

Ọ bụrụ n ’izu ike ma onlyụọ ọgwụ naanị, ị gaghị enwe ike ịkọwa ọnọdụ ahụ.

Onglisa ọgwụ - egosi na ntuziaka maka ojiji

N'ime ọgwụ ndị a na-eji na-agwọ ọrịa shuga, a maara ọgwụ a na-akpọ Onglisa.

Ọ bara uru ịmụ ntuziaka maka ọgwụ a, ịkọwapụta njiri mara ya na uru ya, yana ikpebi ihe ndị ga - enyere aka igbochi mmepe nke mmetụta ọjọọ n'ihi ojiji adịghị mma ya.

Ozi izugbe, ihe mejupụtara na ụdị ịtọhapụ

Ọrịa shuga a dị na United States. Emebere ya iji chịkwaa ọkwa shuga nke ndị ọrịa. Ọ nwere mmetụta hypoglycemic. Jiri ya nke dọkịta ga-akwado ya naanị ka ọ ghara imerụ ahụ ike gị. Ọ bụ ya mere ị ga-eji jiri ọgwụ wee zụta Ongliz.

Ndabere nke ọgwụ bu Saksagliptin. Ọ na-arụ ọrụ bụ isi na ọgwụ a. A na-eji akụrụngwa kwụsị ihe mgbaàmà hyperglycemia site na iwetulata ọkwa glucose ọbara.

Ọ bụrụ na onye ọrịa ahụ ekwenyeghị ndụmọdụ ahụike, mgbe ahụ ọgwụ ahụ nwere ike ibute mmepe nke mmetụta na nsogbu.

Ihe mejupụtara ya nwere ihe inyeaka:

• lactose monohydrate,
• sodium croscarmellose
• hydrochloric acid
• stereti magnesium.

Na mgbakwunye, ọgwụ ahụ nwere obere ọnya, nke achọrọ iji mepụta ihe nkiri maka mbadamba (ọgwụ ahụ nwere ụdị mbadamba).

Ha nwere ike ịdị odo ma ọ bụ pink nwere ihe osise na-acha anụnụ anụnụ. Na ire ere, inwere ike ichu mbadamba ogwu nke 2.5 na 5 mg. A na-ere ha abụọ n'otu ngwugwu sel nke PC 10.

A na-etinye 3 dị otú ahụ na ngwugwu.

Dochie anya dị mma maka mbadamba nke Ongliz

Ihe analogue dị ọnụ ala site na 981 rubles.

Edekwara Galvus maka ọrịa shuga 2, mana ọ dị ọnụ ala karịa ma dị iche na Onglis n'ihe eji arụ ọrụ. Ọ na-eji vildagliptin na usoro nke 50 mg. E nwere ọdịiche na contraindications, tupu ịmalite ọgwụgwọ, gụọ ntuziaka.

Vipidia (mbadamba) Rating: 28 Top

Ihe analogue dị ọnụ ala site na 799 rubles.

Vipidia dịkwa iche na mejupụtara, mana ọ dịkwa na otu ọgwụ ọgwụ dị ka ọgwụ ndị dị n'elu. A na-ejikwa ya maka ụdị ọrịa shuga 2 nke ọrịa mellitus dị ka monotherapy yana yana ndị nnọchianya hypoglycemic ọnụ ma ọ bụ insulin.

Pharmacology na pharmacokinetics

Nsonaazụ nke ọgwụ n’arịa ọrịa shuga bụ n’ihi mpaghara ya n’ọrụ. Mgbe etinyere n’ime ahụ, saxagliptin na-egbochi ihe enzyme DPP-4. N'ihi ya, sel beta dị iche iche na - eme ka insulin na - arụ ọrụ ngwa ngwa. Ọnụ ọgụgụ glucagon n'oge a na-ebelata.

N'ihi njirimara ndị a, a na-ebelata nchịkọta nke glucose n'ọbara onye ọrịa, nke na-eduga na mmezi ọdịmma (ọ gwụla ma ọkwa ya agbadata na ọkwa dị oke mkpa) Akụkụ dị mkpa nke ihe a na-ekwu okwu ya bụ enweghị mmetụta n'akụkụ ya na uru ahụ nke onye ọrịa. Ndị ọrịa na-eji Ongliza enwetaghị ibu.

Mkpuchi nke saxagliptin na-apụta ngwa ngwa ma ọ bụrụ na ị theụọ ọgwụ tupu nri. N'otu oge ahụ, a na-etinye akụkụ dị mkpa nke ihe ahụ na - arụ ọrụ.

Saksagliptin enweghị echiche ịbanye na protein protein - ọdịdị nke agbụ ndị a na-emetụta obere ihe dị na ya. Enwere ike imepụta mmetụta kachasị elu nke ọgwụ ahụ n'ihe dị ka awa 2 (Ngwongwo otu onye na-emetụta nke a). Ọ na-ewe ihe dị ka awa 3 iji kpochapụ ọkara nke Saxagliptin na-abata.

Ihe ngosi na contraindications

Ọ dị ezigbo mkpa ịgbaso ntuziaka maka ngosipụta maka nhọpụta ọgwụ. Iji Onglisa na-enweghị isi na-eweta ahụike dị ukwuu n'ihe gbasara ahụike na ndụ. Ekwesịrị iji ọgwụ ndị nwere mmetụta hypoglycemic naanị maka ndị ahụ nwere nnukwu glucose, maka ndị ọzọ ọgwụ a bụ ihe na-emerụ ahụ.

Nke a pụtara na ngosipụta maka ọgwụ a bụ ọrịa shuga 2. A na-eji ngwa ahụ eme ihe n'ọnọdụ ebe iri nri na mmega ahụ enweghị mmetụta achọrọ na ịka shuga.

Enwere ike iji Onglisa mee ihe abụọ ma yana ọgwụ ndị ọzọ (Metformin, sitere na ụdị sulfonylurea, wdg).

Ọgwụ nwere contraindications:

• ụdị shuga 1
• tụụrụ ime
• nri eke
• anataghi na mejupụtara nke ọgwụ,
• ụkọ lactase
• ọrịa shuga ketoacidosis
• galactose anabataghị ya.

Ọnụnọ ma ọ dịkarịa ala otu ihe sitere na ndepụta ahụ bụ ihe kpatara ịjụ mbadamba.

Kpokwa ndi mmadu n’enyere ikike iji Onglisa, ma n’okpuru nlezianya lebara anya. Ndị a gụnyere ndị agadi, yana ndị ọrịa nwere ọdịda akụrụngwa.

Ntụziaka maka ojiji

Jiri ọgwụ a dịka iwu si dị. Ọ bụrụ na dọkịta edeghị usoro ị differentụ ọgwụ dị iche, mgbe ahụ onye ọrịa ahụ kwesịrị iji 5 mg nke ọgwụ kwa ụbọchị. A na-atụ aro ka a doseụ ọgwụ yiri ya na ijikọ ọnụ nke Onglisa na Metformin (kwa ụbọchị Metformin bụ 500 mg).

Ojiji nke ọgwụ a bụ naanị n’ime. Banyere iri nri, enweghị ihe ngosipụta, ị nwere ike drinkụọ ọgwụ ma tupu nri ma mgbe emesịrị. Naanị ihe ịchọrọ bụ iji ọgwụ ahụ eme ihe na elekere.

Mgbe ị na-egwufe ọgwụ ọzọ, ịkwesighi ichere maka oge a kara aka iji aụọ okpukpu abụọ nke ọgwụ. Ọ dị mkpa iburu akụkụ mbụ nke ọgwụ ahụ ozugbo onye ọrịa chetara ya.

Mmetụta akụkụ na ị andụbiga mmanya ókè

Ọnọdụ nke nsonaazụ ndị ọzọ sitere n'iji Onglisa abụghị mgbe niile ejikọtara ya na ntachi obi ya. Mgbe ụfọdụ, ihe na - akpata ya na - abụ ihe na - adịghị mma na - arụ ọrụ na - emetụtaghị ya Ka o sina dị, ọ bụrụ na achọpụtara ha, a na-atụ aro ịgwa ndị dọkịta banyere ha.

Ntụziaka maka ọgwụ a na-egosi nsonaazụ ndị a dịka:

• urinary tract na-efe efe
• isi ọwụwa
• ọgbụgbọ
• mgbu afọ
• sinusitis
• nasopharyngitis (ya na iji ya na-eme ya na metformin).

A na-eji usoro ọgwụgwọ Symptomatic wepu nsogbu ndị a. N'ọnọdụ ụfọdụ, dọkịta dọkịta kwụsịrị ọgwụ ozugbo.

Enweghị ozi gbasara njirimara nke ọgwụ oke a. Ọ bụrụ na ọ mere, a na-achọpụta ọgwụgwọ Symptomatic.

Echiche onye ọrịa

N'ịtụle nyocha banyere ọgwụ Onglisa ọgwụ, anyị nwere ike ikwubi na ọgwụ ahụ na-ebelata glucose ọbara ọbara nke ọma, mana o dighị onye ọ bụla mma ma chọọ usoro na njikwa onwe onye.

Nsonaazụ sitere na ọgwụ ahụ dị ezigbo mma. Oria m na-akwụ ugbu a, ọ nweghị mmetụta dị n'akụkụ ọ bụla. Na mgbakwunye, ọ na-adaba adaba iji ya.

Dmitry, gbara afọ 44

Ọgwụ Ongliz dị m ka adịghị ike. Ọkpụkpụ glucose agbanwebeghị, ma e wezụga, isi ọwụwa na-egbu m mgbu mgbe niile - o doro anya na ọ nwere mmetụta. Agara m otu ọnwa enweghị ike ịnagide ya; aghaghị m ịrịọ ọgwụ ọzọ.

Alexander, 36 afọ

Ejirila m Onglise afọ atọ. Maka m, nke a bụ ngwaọrụ kachasị mma. Tupu ọ variousụọ ọgwụ dị iche iche, mana nsonaazụ ya pere mpe, ma ọ bụ na ọ na-emekpa ya ahụ. Ugbu a enweghi ụdị nsogbu a.

nchịkọta ọgwụ ọhụụ na ọgwụgwọ ọrịa shuga:

Ọgwụ dị n'etiti ọnụ dị oke ọnụ - ọnụahịa kwa mkpọ bụ pcs 30. ihe dịka 1700-2000 rub. Iji zụta ego, ịchọrọ ndenye ọgwụ.

Akwukwo ndi ozo ndi ozo choro

Onglisa - ọgwụ maka ọrịa shuga

Ọ bụrụ na ọrịa shuga 2dị nke abụọ tolitere, dọkịta na-ahụ maka ịga kwesịrị ịkọwa onye ọrịa ahụ ọgwụ kwesịrị ekwesị.

Otu n'ime akwụkwọ ndị a na-edenyekarị bụ Onglisa.

Tupu ojiji, a na-atụ aro ka ị mụọ ntuziaka maka ojiji, nyocha (ọ dị nnukwu ihe ize ndụ mgbe ejiri ya), analogues na ọnụahịa dị.

Ihe ngosi maka ojiji

N'ime ụdị ọrịa shuga nke 2, ikelata sel nke glucose na-ebelata nke ukwuu. N'oge a, a na-egbu oge na ngalaba mbụ nke njikọta homonụ.

N’ọdị n’ihu, usoro nke abụọ na-efufu n’enweghị nsogbu. Onglisa na-egbu oge igosipụta enzyme DPP 4, incretins dị n'ọbara, a na-emepụta ọtụtụ insulin. Glycemia na-enweghị ume na afọ zuru oke na-agbazi, a na-eweghachi ọrụ nke pancreas. Ya mere, Onglisa na-agbatị ọrụ nke homonụ nke ha, na-abawanye ọdịnaya ha.

Onglisa ọgwụ nwere ụdị ọrịa shuga 2 (na mgbakwunye na nri kwesịrị ekwesị na egwuregwu) ka egosiri dịka:

• ọgwụgwọ mbụ yana ọtụtụ ọgwụ, yana metformin,
• mmata ọgwụ na metformin, insulin, sulfonylureaeri,
• monotherapy.

Ojiji nke Onglises na-edozi njikwa glycemic.

Mpempe mwepụta

Mba nke sitere - USA, mana mbadamba emebere emezi nwere ike ịkwakọ ọnụ na UK ma ọ bụ Italytali.

A na-eme ha n’ụdị mbadamba okirikiri, convex n’akụkụ abụọ ya, a na-ekpuchi akụkụ dị n’elu. Mbadamba ụrọ nke ọ bụla nwere nọmba anụnụ anụnụ. Ngcha nke Onglisa dabere na ntinye uche nke ihe na-arụ ọrụ: 2.5 mg nke ọ bụla bụ ndo ojii na-acha odo odo na-acha ọcha (a na-ede “4214” n'akụkụ nke ọzọ), 5 mg nke ọ bụla bụ pink (nọmba “5” na “4215) ").

Mbadamba nkume ndị ahụ dị na blisters nke emere nke aluminom foil: n'otu ngwugwu 3 blisters nke iberibe 10. Ọkpụkpụ nke ọ bụla nwere ihe na-eme ihe ọ bụla nke na-ekewa ya n'akụkụ 10 (site na ọnụ ọgụgụ mbadamba). A na-echekwa kaadiboodu ka ọ ghara ịdị na-etinye ihe ọ bụla nwere akwụkwọ mmado.

Ọbara shuga dị mgbe niile 3.8 mmol / L

Etu ị gha esi mee ka shuga na nkịtị n’afọ 2019

Nwere ike ịzụta ọgwụ maka Onglizu shuga n'ụlọ ahịa ọgwụ. Na ndenye ọgwụ dị, mana ọ bụghị ndị ahịa ọgwụ niile na-agbaso iwu a. Na 2015, agụnyere ọgwụ ahụ na ndepụta nke ihe ndị dị mkpa, yabụ ọ bụrụ na edebara aha onye ọrịa mamịrị, ọ nwere ike nweta ya n'efu.

Ná nkezi, ọnụ ahịa nkwakọ ngwaahịa maka mbadamba 30 bụ ihe dịka 1800 rubles. Debe ọgwụ ahụ n'ohere na-erughị ogo 30 n’ebe ụmụaka nọ. Nchekwa kwesịrị ịbụ ihe karịrị afọ 3.

Ihe nọ n'ọrụ bụ saxagliptin hydrochloride (2.5 ma ọ bụ 5 mg). Nke a bụ onye nnọchianya nke inhibitor nke oge a nke DPP-4.

Ndị pụrụ iche bụ:

• MCC
• lactose monohydrate,
• sodium croscarmellose
• stereta magnesium,
• hydrochloric acid
• nchara.

Ihe dị na mpụta nke mbadamba ihe mejupụtara OpadryII dai.

Njirimara ngwa

Na nmalite mmalite mgbanwe nke arụ ọrụ akụrụ, ọ dịghị mkpa ịgbanwe usoro onunu ogwu.N'ime nsogbu ndị siri ike karị, ịba ọcha n'anya, ọgwụ akwadoro nke ọgwụ Ongliza bụ 2.5 mg kwa ụbọchị. A na-atụ aro ị Theụ ọgwụ ahụ mgbe usoro ịsacha ọbara dị. Tupu oge ọgwụgwọ, ọ dị mkpa iji nyochaa ọnọdụ akụrụ.

E nyochabeghị mmetụta Onglises n'ahụ na usoro intracorporal nke nsacha ọbara.

Site na mgbanwe na ọrụ imeju, n'agbanyeghị ogo ahụ, ọ dịghị mkpa ịgbanwe otu ọgwụ.

Mmetụta ojiji nke Onglisa na ndị ọrịa shuga karịrị 65 yiri nke ahụ na-emetụta ndị ọrịa na-eto eto. Na ịka nká, ọ dị gị mkpa iwere usoro ị na-eme kwa ụbọchị. Ọ dị mkpa icheta na n'ọkwa a nke uto, ọrụ akụrụ na-agbada, ihe ndị nọ n'ọrụ na-arụ ọrụ nke ha.

Enweghị data banyere ihe egwu na mmetụta dị mma nke Onglisa na-erubeghị afọ 18.

Njikwa njikọta nke Onglisa na insulin n'oge ọgwụgwọ emebeghị nyocha. Enweghị data na nsonaazụ ọgwụ ahụ na-anya na ịnya ụgbọ ala na ihe omume ya na sistem eji arụ ọrụ. Dizziness nwere ike ime mgbe ị theụsịrị ọgwụ.

Amabeghị nsonaazụ ihe dị n’arụ nwanyị dị ime na onye na-actụ nwa.

Enweghị ozi ma ihe ahụ dị ike nwere ike ịbanye na Plasenta na nwa ebu n'afọ yana n’ime mmiri ara, yabụ, edeghị ọgwụ n’oge a.

Ọ bụrụ na ọ gaghị ekwe omume izere iji Onglisa, n'oge ị theụ ọgwụ, a na-akwụsị inye ara. N'okwu a, enwere ike ibute nsogbu nwatakịrị ahụ na nsonaazụ nwere ike ọfụma nke nne.

Ngwunye nke Sulfonylurea na-agbadata ogo glucose dị ala. Iji zere ọrịa dị otú ahụ yana ọgwụgwọ ejikọtara ya na Onglisa, ọ dị mkpa iji belata dose nke sulfonylurea ma ọ bụ insulin.

Site na akụkọ ihe mere eme nke mmeghachi omume siri ike nke nnukwu ndị ọrịa mamịrị (gụnyere mmeghachi omume nfụkasị ozugbo na ụbụrụ Quincke), a dịghị eji Ongliza eme ihe n'oge ndị ọzọ na-egbochi DPP-4. Ọ dị mkpa ịchọpụta ihe nwere ike ịkpata ọrịa obi ma tụọ ọgwụgwọ ọzọ (analogues nke ọgwụ Onglisa).

Enwere ihe akaebe nke nnukwu pancreatitis site na iji ọgwụ. Ekwesịrị ịgwa ndị ọrịa banyere mmeghachi omume dị otú ahụ mgbe ha na-ede akwụkwọ maka Onglisa. Ọ bụrụ na enwere ike gosipụta ihe ngosi nke ihe ịrịba ama mbụ nke pancreatitis, a na-akagbu ọgwụ ahụ.

Mbadamba ahụ nwere lactose, yabụ, ndị ọrịa mamịrị nwere nkwekọrịta mkpụrụ ndụ galactose, ụkọ lactase enweghị ike iwere Onglisa.

Mmekọrịta na ọgwụ ndị ọzọ

Usoro ọgwụgwọ bụ ihe metformin na mkpa maka mgbanwe ndụ. Ọ bụrụ na ụdị ọgwụgwọ ahụ anaghị ebute mmetụta a tụrụ anya, a ga-ewebata ọgwụ ndị ọzọ akwadoro.

Emewo nnyocha nke gosipụtara na enwere obere ihe ize ndụ nke ngwakọta nke saxagliptin na ọgwụ ndị ọzọ.

Iji njikọta nke CYP 3A4 / 5 isoenzymes na-enyere aka belata ọdịnaya nke ngwaahịa metabolic saxagliptin.

Iwere ihe nkpokorita sulfonylurea na -ebelata mkpocha glucose na obara. Iji gbochie ụdị ihe egwu a, ọ dị mkpa iji belata ọgwụ Onglisa nke ọgwụ.

Enwebeghị ọmụmụ ọ bụla emere na ị ofụ sịga, nri, ma ọ bụ ị drinkingụ mmanya na saxagliptin.

Ihe eji akpachapụ anya

Onglisa bụ ọgwụ dị mma ọfụma, nsonaazụ echeghị echekwa na ọ anaghị adụ. Enwere ọtụtụ mmeghachi omume na-adịghị mma na saxagliptin dịka a na-enweta ọgwụgwọ placebo.

Amachibidoro iji Onglises mgbe:

• ụdị shuga 1
• ngalaba na insulin
• ụkọ lactase,
• ọrịa mamịrị ketoacidosis,
• tụụrụ ime
• inye ara
• n'okpuru afọ 18
• mmadụ ịhapụ n'otu akụkụ nke ọgwụ ahụ.

Ọ dị ezigbo mkpa ka ndị ọrịa jiri:

• na-ata ahụhụ site na arụ ọrụ nzilata adịghị ala ma ọ bụ nnukwu nsogbu akụrụngwa n'oge gara aga,
• ndị agadi
• ya na iji ya na sulfonylureas.

N'oge ọgwụgwọ Onglisa, enwere ọghọm nke ọghọm ya:

• urinary tract na-efe efe
• ọrịa akụkụ akụkụ okuku ume na nke elu
• mbufụt nke mucosa sinus,
• afọ nke ime afọ na obere eriri afọ,
• gagging
• nnukwu pancreatitis
• migraine.

Site na iji ọgwụgwọ agwakọta na metformin, nasopharyngitis na-egosipụta onwe ya n'ọnọdụ ụfọdụ.

Achọpụtara hypersensitivity na 1.5% nke ikpe, ọ tinyeghị ndụ egwu, ọ chọghịkwa ka ụlọ ọgwụ gaa.

Mgbe ejikọtara ya na thiazolidinediones, na-ekpe ikpe site na nyocha nke Onglise, a chọpụtara na mmebi edema na-adịghị ike ma ọ bụ na-agafeghị oke, nke na-achọghị nkwụsị ọgwụgwọ.

Ihe kpatara hypoglycemia n'oge ọgwụgwọ Ongliza dabara na nsonaazụ ya na placebo.

Dodoụbiga ya ókè

Site n'iji oke ọgwụ ahụ ogologo oge, akọwaghị ihe ịrịba ama nke nsi. Ọ bụrụ n ’ịdoụbiga mmanya ókè, a ga-ewepụtụ ihe mgbaàmà. Ihe na-arụ ọrụ na ngwaahịa metabolic dị na ya bụ hemodialysis wepụrụ ya.

Analogs Onglises nwere otu ihe arụ ọrụ adịghị adị. Nke a bụ naanị ọgwụ nwere saxagliptin. Otu mmetụta ahụ na-arụ ọrụ n'ahụ bụ Nesin, Transient, Galvus. Amachibidoro iji ọgwụ analogues Ongliz n'enweghị ikike nke dọkịta na-abịa.

Ọgwụ shuga nke Onglis na-enyere aka idobe glucose ọbara. Erere dị mma iji were. Apụrụ m ịchọpụta uru m na-edebeghị. N'ime minuses, apụrụ m ịkpọ aha ndị riri oke ego.

Onglisa ọgwụ ahụ masịrị m, enwere ntụziaka doro anya maka ojiji, ọ dị mfe iji. Mgbe ụfọdụ isi ọwụwa na - apụta. Ana m akwado ọgwụ ahụ.

Ongliza ogwu bu onye nnochite anya ndi ohuru nke mmanu di ala. O nwere usoro dị iche iche nke mmetụta, mana n’ihe gbasara arụmọrụ ọ yiri ọgwụ ọdịnala, na nchekwa ọ karịrị ha. Ọgwụ nwere mmetụta dị mma na ọrịa concomitant, na-egbochi ọganihu nke ọrịa shuga na nsogbu.

Uru ndị a na-enweghị mgbagha bụ enweghị ihe egwu nke hypoglycemia, nsonaazụ na ibu onye ọrịa yana ohere iji ọgwụ shuga ndị ọzọ belata. N'ọdịnihu, ndị sayensi bu n’obi kee ọgwụ nke ga-eweghachi ọrụ akwara afọ.

Ọrịa shuga na-edugakarị ọrịa na-egbu egbu. Oké ọbara shuga dị oke ize ndụ.

Lyudmila Antonova na Disemba 2018 nyere nkọwa gbasara ọgwụgwọ ọrịa shuga. Na-agụ zuru ezu

Isiokwu ahụ nyeere aka?

Ọgwụ Onglisa sitere na ọrịa shuga mellitus - ntuziaka zuru ezu maka ojiji

Ọrịa a na - emetụta 9% nke ndị bi n'ụwa. Ndị ụlọ ọrụ ọgwụ na usoro ahụike nke mba ndị isi ụwa na-etinye ọtụtụ ijeri dollar, ọrịa shuga na-enwe mmeri gburugburu ụwa, na-etolite, na-emewanye ihe ike.

Ọrịa a na-ewere ọnụego ndị a na-atụghị anya ya: ka ọ na-erule 2020, e bukwara na ọkara ndị ọrịa nwere ụdị ọrịa shuga 2, ndị dọkịta amụtakwala otu esi ejikwa ọrịa ahụ n'ụzọ dị irè.

Ọ bụrụ na enwere ụdị shuga nke 1, nke na-emetụta ihe na-erughị 10% nke ndị ọrịa mamịrị, ihe niile dị mfe: belata mkpokọta glucose na ọbara n'ọbara site na ịbanye insulin (ọ nweghị ihe ọzọ enwere ike inye ya ebe ahụ) na ihe niile ga-adị mma (taa, maka ndị ọrịa dị otú a, ha mepụtara ihe na-eme ka ọria ahụ. ), mgbe ahụ ya na ụdị ọrịa shuga 2, teknụzụ dị elu anaghị arụ ọrụ.

Site na ntụnyere, maka ụdị shuga 2, shuga a kwụrụ bụ onye iro kachasị, na-ejupụta ahịa n’ahịa ọgwụ na-ebelata shuga. Mee ka ọgwụgwọ nke ndị ọrịa mamịrị jiri enyemaka nke pyramid ọgwụgwọ, mgbe etinyere ọgwụ ọzọ na otu ọgwụ, mgbe ahụ, a na-agbakwunye ọgwụ nke atọ na usoro a, ruo mgbe oge insulin ruru.

N'ime afọ 20 gara aga, ndị dọkịta na-agbasi ike na shuga, ma mmetụta ọ dị n'okpuru efu, ebe ọ bụ na nsonaazụ yana nsonaazụ sitere na ọgwụ ọgwụ na-akachasị uru ha, ọkachasị ma ọ bụrụ na ị soghị usoro ị doụ ọgwụ ahụ, eburula n'uche onye ọgwụ kwesịrị ekwesị na onye na-adịghị.

Otu n’ime akụkụ ahụ ndị a chọrọ iche bụ mkpụrụobi na akwara ọbara. Achọpụtala na ịgwọ ọrịa shuga dị ukwuu na-enye nsonaazụ na-eduga ma na-eduga na ịnwụ akwara. Sugar bụ naanị akara nke ụdị shuga 2; ọrịa ahụ sitere na metabolic syndrome.

Ọgwụ nke ọgbọ ọhụrụ Onglisa, nke ndị ọkà mmụta sayensị Britain na Italiantali mepụtara, nwere ọ bụghị naanị antidiabet, kamakwa ike cardioprotective. Ogwu nke usoro ihe omumu a, nke gunyere Onglisa, bu ihe ohuru ohuru banyere oru a. Ha na - arụ ọrụ iji belata agụụ na ịbelata ibu - otu n'ime isi ihe kpatara mmepe nke ụdị shuga 2.

Na mgbakwunye, incretinomimetik anaghị akpalite hypoglycemia, nyere aka belata ọbara mgbali, ma chebe mkpụrụ ndụ akwara. Enwere ike ịpụta ọghọm nke Onglisa, mana nke ahụ anaghị enwe ahụmịja n'ihi obere oge nke ị theụ ọgwụ ọjọọ, mana nke a bụkwa ihe oge.

Ngwakọta na ụdị ntọhapụ

Mbadamba akwụkwọ Onglisa nke ọ bụla, foto nke ewepụtara na nkebi a, nwere 2.5 mg ma ọ bụ 5 mg nke saxagliptin hydrochloride na shei ahụ. Emebere usoro ahụ na ndị na - eme nri: cellulose, lactose monohydrate, ssumum croscarmellose, magnesium stearate na Opadray dyes (ọcha, odo na acha anụnụ anụnụ maka mbadamba 2.5 mg na ọcha, pink na acha anụnụ anụnụ maka iji ọgwụ eme ihe 5 mg).

Enwere ike mata ọgwụ a site na udi (mbadamba biconvex nwere agba odo na akara akara 2.5 / 4214 na pinkish na osise 5/4215). Ihe a na-eji edetu akara a akara n'akụkụ ya ọ bụla.

Nwere ike ịzụta ọgwụ ndenye ọgwụ. Maka mbadamba nkume Ongliz, ọnụahịa esiteghị na ngalaba mmefu ego: maka pcs iri atọ. 5 mg na Moscow ịkwesịrị ịkwụ ụgwọ 1700 rubles. Emeputa kpebiri ndụ nchekwa nke ọgwụ n’ime afọ atọ. Ọnọdụ nchekwa maka ọgwụ ahụ bụ ọkọlọtọ.

Njirimara nke ogwu

Ihe kachasị na Onglisa bụ saxagliptin. N'ime otu ụbọchị ịbanye n'ime ngba ahụ, ọ na-egbochi ọrụ nke peptide DPP-4. Na kọntaktị glucose, mwepu nke enzyme ahụ nke ukwuu (ugboro 2-3) na-eme ka ihe nzuzo glucose dị ka peptide-1 (GLP-1) yana glucose na-adabere glucose polypeptide (HIP).

N'otu oge, ọkwa glucagon n'ime sel-agbada na-ebelata, ọrụ nke b-sel na-ahụ maka mmepụta insulin endogenous na-abawanye. N'ihi ya, a na-ebelata ihe ngosipụta nke ibu ọnụ na postprandial glycemia nke ukwuu.

A mụrụ nchekwa na arụmọrụ nke ọgwụ ahụ na nnwale 6, ebe ndị ọrụ afọ ofufo 4148 nwere ụdị 2 sonyere.

Ndị niile sonyere gosipụtara ike dị mma na haemoglobin glycated, shuga agụụ na glycemia mgbe ha nwesịrị ikike carbohydrate.

Enyere ọgwụ ndị ọzọ, dịka thiazolidinediones, metformin, glibenclamide, ka enyere ndị niile sonyere na-agabeghị nchịkwa glycemic 100%.

Banyere Onglise, nyocha nke ndị ọrụ afọ ofufo ndị sonyere na nnwale ndị yiri nnwale na-egosi na, na usoro dị iche iche, gemoclobin glycated na ihe mejupụtara ọbara ka mma mgbe izu abụọ gachara.

Ndị ọrịa na-a additionalụ ọgwụ mgbochi ọrịa ọzọ gosipụtara nsonaazụ yiri ya. Oke nke ndị niile sonyere na nyocha ahụ kwụgidere.

Ogwu hypoglycemic ọgwụ

Omume ọgwụ

Saxagliptin nwere ike ịhọrọ nke ga - agbanwegharị dipeptidyl peptidase-4 (DPP-4) inhibitor.

N'ime ndị ọrịa nwere ụdị ọrịa shuga 2 nke ọrịa mellitus, nchịkwa nke saxagliptin na-eduga n'ịkwụsị ọrụ enzyme DPP-4 ruo awa 24.

Mgbe ịbịnyechara glucose, mgbochi nke DPP-4 na-eduga na mmụba okpukpu abụọ na ntinye nke glucagon-pe pepeide-1 (GLP-1) na glucose na-adabere na polypeptide glucose (HIP), mbelata mgbanye glucagon na mmụba na nzaghachi beta nke glucose, nke na-eduga n'ọbawanye na mkpokọta cell, insulin na C-peptide.

Mwepụta nke insulin site na mkpụrụ ndụ beta nke pancreatic yana mbelata nke ịtọhapụ glucagon site na mkpụrụ ndụ alịcreatic na-eduga na mbelata nke glycemia na-ebu ọnụ na postprandial glycemia.

A mụrụ ịdị mma na nchekwa nke saxagliptin mgbe ewere ya na usoro mg 2,5, 5 mg na 10 mg 1 oge / ụbọchị n'ime ọmụmụ abụọ kpuru ìsì, placebo na-achịkwa na ndị ọrịa 4148 nwere ụdị ọrịa 2.

Tụ ọgwụ ahụ nwere nnukwu mmụba dị ukwuu na ọbara glycosylated hemoglobin (HbA1c), glucose plasma glucose (GPN) na plasma glucose postprandial (PPG) ma e jiri ya tụnyere njikwa.

Ndị ọrịa a na-ejikọghị akara nke glycemic na saxagliptin dị ka monotherapy edekwara metformin, glibenclamide ma ọ bụ thiazolidinediones.

Mgbe ị na-ewere saxagliptin na 5 mg, a hụrụ nbelata HbA1c mgbe izu anọ na GPN gasịrị izu abụọ.

N'ime ìgwè ndị ọrịa na-anata saxagliptin na metformin, glibenclamide ma ọ bụ thiazolidinediones, a hụrụ nbelata HbA1c mgbe izu anọ na GPN gasịrị izu abụọ.

Mmetụta saxagliptin na profaịlụ nke egbugbere ọnụ yiri nke placebo. N'oge ọgwụgwọ saxagliptin, ọ nweghị mmụba dị arọ n'ahụ ama ama ama.

Mlọ ọgwụ

N'ime ndị ọrịa nwere ụdị ọrịa mellitus 2 dị mma na ndị ọrụ afọ ofufo nwere ahụ ike, a chọpụtara ọgwụ ọgwụ yiri nke saxagliptin na metabolite isi ya.

Saxagliptin na-agbakarị ngwa ngwa mgbe ịba n'ime oghere efu na mmezu nke Cmax nke saxagliptin na metabolite isi na plasma ruo elekere 2 na awa anọ.

Site na mmụba na dose nke saxagliptin, ekwuru mmụba na Cmax na AUC nke saxagliptin na metabolite bụ isi ya.

Mgbe otu nchịkwa ọnụ nke saxagliptin dị na 5 mg site na ndị ọrụ afọ ofufo nwere ahụ ike, nkezi ụkpụrụ AUC nke saxagliptin na metabolite ya bụ isi nke 78 ng × h / ml na 214 ng × h / ml, na ụkpụrụ plasma Cmax bụ 24 ng / ml na 47 ng / ml, n'otu n'otu .

Ogologo oge T1 / 2 nke ikpeazụ nke saxagliptin na metabolite ya bụ isi bụ awa 2.5 na awa 3.1, n'otu aka ahụ, nkezi mgbochi inhibition T1 / 2 nke DPP-4 bụ 26,9 awa.

Mkpuchi nke ọrụ DPP-4 plasma dịkarịa ala elekere 24 ka emesịrị saxagliptin bụ n'ihi ịdị elu ya maka DPP-4 yana ogologo oge iji kegide ya. Achọpụtaghị nnukwu ihe mejupụtara ọgwụ zirigliptin na metabolite ya na iji ọgwụ ogologo oge oge 1 ụbọchị.

Enweghi ihe ndabere nke nhicha nke saxagliptin na metabolite ya kachasị na usoro ọgwụ na oge ọgwụgwọ mgbe ị na-ewere saxagliptin 1 oge / ụbọchị na usoro onunu si 2.5 mg ruo 400 mg maka ụbọchị 14.

Mgbe nchịkwa ọnụ gasịrị, ọ dịkarịa ala 75% nke dose nke saxagliptin na-abanye. Iri nri emetụtaghi ọgwụ pharmokokinetics nke saxagliptin na ndị ọrụ afọ ofufo ahụ siri ike.

Nri buru ibu emetụtaghi Cmax nke saxagliptin, ebe AUC mụbara site na 27% ma e jiri ya na-ebu ọnụ. Oge ị ga-eru Cmax maka saxagliptin mụbara site na ihe dịka 0.

Nkeji 5 mgbe ị na-a theụ ọgwụ ọjọọ na nri ma e jiri ya tụnyere ibu ọnụ. Agbanyeghị, mgbanwe ndị a adịchaghị mkpa n'ịgwọ ọrịa.

Njikọ nke saxagliptin na metabolite ya na protein protein n'ọbara abụghị ihe dị mkpa; yabụ, enwere ike iche na nkesa nke saxagliptin na mgbanwe na protein protein nke ọbara ọbara hụrụ na hepatic ma ọ bụ akụrụ agaghị enwe nnukwu mgbanwe.

Saxagliptin bụ metabolized tumadi na ntinye nke isoenzymes nke cytochrome P450 3A4 / 5 (CYP 3A4 / 5) na nguzobe nke metabolite dị ike, mmetụta inhibitory nke megidere DPP-4 bụ ugboro abụọ adịghị ike karịa nke saxagliptin.

Saxagliptin dị na mmamịrị na bile. Mgbe otu ọgwụ were 50 mg nke akara 14C-saxagliptin, 24% nke dose ahụ ka akụrụ na-agbanwe agbanwe dịka saxagliptin na-agbanweghị na 36% dị ka metabolite nke saxagliptin.

Ngụkọta akwara ozi hụrụ na mmamịrị ruru 75% nke ọgwụ a .ụrụ.Nkezi mkpocha ezigharịrị nke saxagliptin dị ihe dị ka 230 ml / min, uru gbachapụrụ agbacha gbacha gbacha gbata ruru 120 ml / min.

Maka isi metabolite, mkpochapu akụrụ bụ ihe pụtara na uru nke ikpocha ụwa.

Ihe dị ka pacenti 22% nke ikuku redio a hụrụ na feces.

Pharmacokinetics n'ihe gbasara ọrịa

N'ime ndị ọrịa nwere ezughi oke gbasara akụrụ, ụkpụrụ nke AUC nke saxagliptin na metabolite ya kachasị elu bụ 1.2 na 1.7 karịa, n'otu n'otu, karịa ndị mmadụ nwere ọrụ gbasara ọrụ nkịtị. Mmụba a na ụkpụrụ AUC abụghị ihe dị mkpa gbasara ụlọ ọgwụ, ya mere, ọ chọghị ịmegharị dose.

N'ime ndị ọrịa nwere obere akụrụ na-ada ada, yana ndị ọrịa metụtara n'ọrịa akụrụ ụkwụ, ụkpụrụ AUC nke saxagliptin na metabolite bụ isi ya bụ 2.1 na 4, n'otu n'otu.

5 dị elu karịa ihe ngosi ndị yiri ya na ndị nwere ọrụ ezumike ọrụ nkịtị.

Maka ndị ọrịa nwere obere akụrụngwa arụ ọrụ, yana ndị ọrịa na hemodialysis, mkpụrụ nke saxagliptin kwesịrị ịbụ 2.5 mg 1 oge / ụbọchị.

N'ime ndị ọrịa nwere ọria nkwarụ dị nro, na-agafe agafe, ọ nweghị mgbanwe dị egwu na ọgwụ ọgwụ nke saxagliptin, ya mere, a chọghị ịgbanwe mgbanwe maka ndị ọrịa dị otú ahụ.

N'ime ndị ọrịa dị afọ 65-80, enweghị ọdịiche pụtara ìhè dị na pharmacokinetics nke saxagliptin ma e jiri ya tụnyere ndị ọrịa dị obere (afọ 18-40), yabụ, achọrọ nhazigharị ọgwụgwọ na ndị ọrịa agadi. Agbanyeghị, ekwesịrị iburu n'uche na n'ụdị ndị ọrịa a, mbelata ọrụ akụrụ nwere ike ịdị.

Elldị shuga mellitus 2 na mgbakwunye na nri na mmega iji melite njikwa glycemic na ogo:

- na - amalite usoro ọgwụgwọ na metformin,

- agbakwunye na monotherapy nwere metformin, thiazolidinediones, usoro nke sulfonylurea, na enweghị enweghị nchịkwa glycemic zuru oke na usoro ọgwụgwọ a.

Edere ọgwụ a n'ọnụ, n'agbanyeghị nri ị ga-eri.

Na monotherapy usoro akwadoro nke saxagliptin bụ 5 mg 1 oge / ụbọchị.

Na ngwakọta ọgwụgwọ usoro akwadoro ziri ezi nke saxagliptin bụ 5 mg 1 oge / ụbọchị yana agwakọta na metformin, thiazolidinediones ma ọ bụ usoro sulfonylurea.

Na ịmalite njikọta ọgwụgwọ na metformin usoro akwadoro nke saxagliptin bụ 5 mg 1 oge / ụbọchị, usoro mbụ nke metformin bụ 500 mg / ụbọchị. N'ihe banyere nzaghachi ezughị ezu, enwere ike ịbawanye dose nke metformin.

Na gafere nke ị theụ ọgwụ Ongliza nke mbubreyo ga-ewere ozugbo ozugbo onye ọrịa chetara nke a, ị ga-ewere ya okpukpu abụọ nke ọgwụ otu ụbọchị.

N'ihi na ndị ọrịa nwere ọdịda obere aha (KK> 50 ml / mina) achoghi ndozi uzo.

N'ihi na ndị ọrịa nwere ezughi oke gbasara akụrụ (KK ≤50 ml / min), yana kwa ndị ọrịa na-arịa ya ọgwụ a tụrụ aro maka Ongliza bụ 2.5 mg 1 oge / ụbọchị. Ekwesịrị ị drugụ ọgwụ ahụ na njedebe nke nnọkọ hemodialysis.

Amabeghị ojiji nke saxagliptin na ndị ọrịa na-ele mgbaaka peritoneal dialysis. Tupu ịmalite ọgwụgwọ na saxagliptin na n'oge ọgwụgwọ, a na-atụ aro ka ị nyochaa ọrụ akụrụ.

Na arụ ọrụ imeju na-arụ ọrụ nwayọ, na-agafekwa oke ma sie ike ekwesighi imeghari dose.

Dose ukpụhọde ke ndị ọrịa agadi achoghi ya. Agbanyeghị, mgbe ị na-ahọrọ ọgwụ, ekwesịrị iburu n'uche na n'ụdị ndị ọrịa a, mbelata ọrụ ọrụ akụrụ nwere ike ịdị.

Nchedo na nrụpụta ọrụ nke ọgwụ in ndị ọrịa na-erubeghị afọ 18 agụghị akwụkwọ.

Na iji ihe eji eme ya eme ihe na ike CYP 3A4 / 5 inhibitorsdị ka ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir na telithromycin, ọgwụ a tụrụ aro Ongliza bụ 2.5 mg 1 oge / ụbọchị.

Ugboro ugboro nke ihe ojoo mgbe ị na-ewere Ongliza 5 mg na monotherapy na ọnọdụ nke mgbakwunye ọgwụgwọ na metformin, thiazolidinedione ma ọ bụ glibenclamide yiri nke ahụ na otu placebo.

Ole ugboro ole nke mmeghachi omume dị njọ: ọtụtụ mgbe (≥1 / 10), ọtụtụ mgbe (≥1 / 100,

Onglisa: ogwu maka oria shuga, nyocha na analogues nke mbadamba

Site na ọganihu nke ọrịa shuga na-enweghị insulin, ndị ọrịa anaghị enwe ike ịchịkwa ọkwa nke glycemia site na iji nri pụrụ iche na mmega ahụ. Onglisa bụ ọgwụ na-ewedata shuga nke ejiri mee ihe n'ụdị ndị a iji mee ka obi glucose dị n'ọbara.

Dịka ọgwụ ọ bụla, Onglisa nwere ụfọdụ contraindications, mmeghachi omume na-adịghị mma, yana atụmatụ ojiji. Ya mere, tupu ị usingụ ọgwụ ahụ, ịkwesịrị ịchọpụta ozi zuru ezu banyere ya.

Onglisa (in lat. Onglyza) bu ogwu ama ama ama eji eji uwa nile maka oria 2. Aha mba ụwa (INN) nke ọgwụ bụ Saxagliptin.

Onye mepụtara ụdị hypoglycemic a bụ ụlọ ọrụ ọgwụ America bụ Bristol-Myers Squibb. A na - ahụta akụrụngwa bụ isi - saxagliptin bụ otu n'ime ihe kachasị ike na - ahọgharị ndị ga - achọgharị nke dipeptidyl peptidase-4 (DPP-4). Nke a pụtara na mgbe ejiri ọgwụ ọnụ were ọgwụ ahụ, ihe bụ isi na-egbochi ọrụ enzyme DPP-4 n'ụbọchị.

Na mgbakwunye saxagliptin, mbadamba nke Onglis nwere obere obere ihe ndị ọzọ - lactose monohydrate, ssumum croscarmellose, microcrystalline cellulose, macrogol, talc, titanium dioxide, magnesium stearate na ụfọdụ ndị ọzọ. Dabere n'ụdị ntọhapụ, otu mbadamba ọgwụ ahụ nwere ike ịnwe 2.5 ma ọ bụ 5 mg nke ihe na-arụ ọrụ.

Kedụ ka onye antidiabetic wakpo Onglisa si eme ihe mgbe ọ batasịrị ahụ mmadụ? Saxagliptin na-abanye na ngwa ngwa nri, a na-ahụ ọdịnaya ya kachasị na plasma ọbara n'ọbara 2-4 mgbe ejiri ya. Ọgwụ nwere mmetụta dị otú a:

1. Na-abawanye ọkwa nke ISU na GLP-1.
2. Na-ebelata ọdịnaya nke glucagon, na-emekwa ka mmeghachi omume nke mkpụrụ ndụ beta dị, nke gụnyere mmụba na ọkwa C-peptides na insulin.
3. Ọ na-akpalite mwepụta nke homonụ na - eme ka okpukpo dị ala site na mkpụrụ ndụ beta dị na akwara.
4. Na-egbochi iwepụta glucagon site na mkpụrụ ndụ alfa nke agwaetiti nke Langerhans.

Site na iweghachite usoro ndị a dị n’elu ahụ, ọgwụ Onglis na-eme ka uru dị n’ahụ glycated haemoglobin (HbA1c), ndị na-egosi glucose na afọ na-enweghị isi na mgbe ha riri nri. Ndi dibia nwere ike ideputa ogwu ahu na aru ndi ozo hypoglycemic (metformin, glibenclamide ma obu thiazolidinediones).

A na-ewepụta ihe ndị nọ n'ọrụ n'ahụ ahụ n'ụdị na-agbanweghi agbanwe yana n'ụdị metabolite na bile na mmamịrị.

Na nkezi, mkpochapu nke renigliptin bụ 230 ml kwa nkeji, ọnụego nhichapụta nke ụwa (GFR) bụ 120 ml kwa nkeji.

Tupu ị theụọ ọgwụ ahụ, onye ọrịa ahụ kwesịrị ịkpọtụrụ ọkachamara ahụike ya nke ga-ekpebi usoro onye ọ bụla dabere na ọkwa shuga. Mgbe ị na-azụ ọgwụ Onglisa, ntuziaka maka ojiji a ga-agụ nke ọma ma ọ bụrụ na ị nwere ajụjụ jụọ dọkịta ha.

A na-eji mbadamba mee ihe n'agbanyeghị oge nri, jiri mmiri mmiri sachaa ya. Ọ bụrụ na a theụrụ ọgwụ ahụ dị ka monotherapy, mgbe ahụ, ọgwụ kwa ụbọchị bụ 5 mg. Ọ bụrụ na dọkịta depụtara ọgwụ ejikọtara ọnụ, mgbe ahụ, a ga-ahapụ otu ụbọchị ka Onglisa pụtara 5 mg na metformin, thiazolidinediones na ọgwụ hypoglycemic ndị ọzọ.

Na ijikota Onglisa na metformin, ikwesiri igbaso usoro izizi nke 5 mg na 500 mg. A machibidoro ya iwu ịsụ okpukpu abụọ nke ikpe ahụ mgbe onye ọrịa chefuru ị theụ ọgwụ n'oge. Ozugbo o chetara nke a, ọ kwesịrị ị drinkụ otu ọgwụ.

Nke kachasị dị mkpa bụ ndị ọrịa na-ata ahụhụ site na ọdịda akụrụ. Site n'ụdị dị nrịba nke akụrụngwa akwara, ọ dịghị mkpa iji dozie dose nke ọgwụ. N'ime ndị ọrịa nwere obere akụrụ oke ma ọ bụ daa oke, yana ndị na-arịa hemodialysis, usoro ubochi bụ 2.5 mg. Na mgbakwunye, mgbe ị na-eji ọgwụ mgbochi CYP 3A4 / 5 siri ike, ị ofụ ọgwụ Onglis kwesịrị ịdị ntakịrị (2.5 mg).

Onye rụpụtara ya na-egosi n’echibido ụbọchị mmechi, nke na-abụkarị afọ 3. A na-echekwa ọgwụ ahụ n'aka ụmụaka na-eto eto na-enweghị ogo 30.

Mbadamba ihe mkpuchi site na odo odo na-acha odo odo na-acha odo odo na agba, gburugburu, biconvex, nke e dere “2.5” n'otu akụkụ yana “4214” n'akụkụ nke ọzọ, nke a na-eji acha anụnụ anụnụ na-acha anụnụ anụnụ.

Ndị na-ahụ maka ihe: lactose monohydrate - 99 mg *, celclosese microcrystalline - 90 mg, ssumum croscarmellose - 10 mg, magnesium stearate - 1 mg **, hydrochloric acid 1 M ma ọ bụ sodium hydroxide solution 1 M - ọnụ ọgụgụ achọrọ, Opadry II white (% arọ / aro) - 26 mg (polyvinyl mmanya 40%, titanium dioxide 25%, macrogol (PEG 3350) 20.2%, talc 14.8%), Opadry II odo (% ibu / ibu) - 7 mg (polyvinyl mmanya 40%, titanium dioxide titanium 24.25%, macrogol (PEG 3350) 20,2%, talc 14.8%, dye iron oxide yellow (E172) 0.75%), ink Opacode acha anụnụ anụnụ *** - ego achọrọ.

10 PC. - aluminom foil blisters (3) - ngwugwu nke kaadiboodu.

* Ofgwọ lactose nwere ike ịdị iche dabere na nha magnesium stearate eji.
** Ole magnesium stearate nwere ike ịdị iche n'etiti 0,5-2 mg. Ezigbo ego nke 1 mg.
*** Ihe mejuputara Opacode acha anụnụ anụnụ (% ibu / ibu): shellac 45% na ethyl mmanya 55.4%, FD&C Blue # 2 / indigo carmine aluminom pigmenti (Е132) 16%, n-butyl mmanya 15%, propylene glycol 10.5%, mmanya mmanya isopropyl 3%, 28% ammonium hydroxide 0.1%. Onu pere mpe nke shellac na FD&C Blue # 2 / indigo carmine aluminom na-adi n’elu mbadamba ihe mgbe akara. A na-ewepụ solvent ndị dị na ink ink n'oge a na-emepụta ya.

Mbadamba ihe mkpuchi pink, okirikiri, biconvex, ya na ihe odide "5" n'otu akụkụ yana "4215" n'akụkụ nke ọzọ, na-acha anụnụ anụnụ na-acha anụnụ anụnụ.

Ndị na-ahụ maka ihe: lactose monohydrate - 99 mg *, celclosese microcrystalline - 90 mg, ssumum croscarmellose - 10 mg, magnesium stearate - 1 mg **, hydrochloric acid 1 M ma ọ bụ sodium hydroxide solution 1 M - ọnụ ọgụgụ achọrọ, Opadry II white (% arọ / aro) - 26 mg (polyvinyl mmanya 40%, titanium dioxide 25%, macrogol (PEG 3350) 20.2%, talc 14.8%), Opadry pink pink (% ibu / ibu) - 7 mg (polyvinyl mmanya 40%, titanium dioxide titanium 24.25%, macrogol (PEG 3350) 20.2%, talc 14.8%, dye iron oxide red (E172) 0.75%), ink Opacode acha anụnụ anụnụ *** - ego achọrọ.

10 PC. - aluminom foil blisters (3) - ngwugwu nke kaadiboodu.

* Ofgwọ lactose nwere ike ịdị iche dabere na nha magnesium stearate eji.
** Ole magnesium stearate nwere ike ịdị iche n'etiti 0,5-2 mg. Ezigbo ego nke 1 mg.
*** Ihe mejuputara Opacode acha anụnụ anụnụ (% ibu / ibu): shellac 45% na ethyl mmanya 55.4%, FD&C Blue # 2 / indigo carmine aluminom pigmenti (Е132) 16%, n-butyl mmanya 15%, propylene glycol 10.5%, mmanya mmanya isopropyl 3%, 28% ammonium hydroxide 0.1%. Onu pere mpe nke shellac na FD&C Blue # 2 / indigo carmine aluminom na-adi n’elu mbadamba ihe mgbe akara. A na-ewepụ solvent ndị dị na ink ink n'oge a na-emepụta ya.

Saxagliptin nwere ike ịhọrọ nke ga - agbanwegharị dipeptidyl peptidase-4 (DPP-4) inhibitor.

N'ime ndị ọrịa nwere ụdị ọrịa shuga 2 nke mellitus, nchịkwa nke saxagliptin na-egbochi ọrụ nke enzyme DPP-4 maka awa 24. Mgbe ịba ụba glucose, mmachi nke DPP-4 na-eduga na mmụba okpukpu abụọ na glucagon-like peptide-1 (GLP-1) na glucose-based insulinotropic glucose. polypeptide (HIP), mbelata nke mkpokọta glucagon yana mmụba na nzaghachi glucose nke mkpụrụ ndụ beta, nke na-eduga n'ịbawanye ụba nke insulin na C-peptide.

Mwepụta nke insulin site na mkpụrụ ndụ beta nke pancreatic yana mbelata nke ịtọhapụ glucagon site na mkpụrụ ndụ alịcreatic na-eduga na mbelata nke glycemia na-ebu ọnụ na postprandial glycemia.

A mụrụ ịdị mma na nchekwa nke saxagliptin mgbe ewere ya na usoro mg 2,5, 5 mg na 10 mg 1 oge / ụbọchị n'ime ọmụmụ abụọ kpuru ìsì, placebo na-achịkwa na ndị ọrịa 4148 nwere ụdị ọrịa 2. Takingụ ọgwụ ahụ bụ nnukwu mmụba pụtara statistiki na glycated glucose (HbA)_1c), plasma glucose na-ebu ọnụ (GPN) na ọbara mgbakwunye postprandial glucose ọbara (PPG) ma e jiri ya tụnyere njikwa.

Ndị ọrịa a na-ejikọghị akara nke glycemic na saxagliptin dị ka monotherapy edekwara metformin, glibenclamide ma ọ bụ thiazolidinediones. Mgbe ị na-ewere saxagliptin na ọgwụ nke 5 mg, mbelata na HbA_1c amaara ka izu anọ na GPN gasịrị - ka izu abụọ gasị. N'ime ìgwè ndị ọrịa na-anata saxagliptin yana metformin, glibenclamide ma ọ bụ thiazolidinediones, mbelata na HbA_1c kwukwara na mgbe izu anọ na GPN gasịrị - ka izu abụọ gachara.

Mmetụta saxagliptin na profaịlụ nke egbugbere ọnụ yiri nke placebo. N'oge ọgwụgwọ saxagliptin, ọ nweghị mmụba dị arọ n'ahụ ama ama ama.

N'ime ndị ọrịa nwere ụdị ọrịa mellitus 2 dị mma na ndị ọrụ afọ ofufo nwere ahụ ike, a chọpụtara ọgwụ ọgwụ yiri nke saxagliptin na metabolite isi ya.

Saxagliptin na-agbakarị ngwa ngwa mgbe ịbanyesịrị na afọ na-enweghị isi na mmezu nke C_max saxagliptin na isi metabolite na plasma maka 2 awa na awa anọ, n’otu n’otu. Site na mmụba na ọgwụ ziri ezi saxagliptin, ekwuputere abawanye na C_max na AUC nke saxagliptin na metabolite isi ya. Mgbe otu nchịkwa ọnụ nke saxagliptin dị na 5 mg site na ndị ọrụ afọ ofufo nwere ahụ ike, nkezi ụkpụrụ AUC nke saxagliptin na metabolite ya bụ isi nke 78 ng × h / ml na 214 ng × h / ml, yana C_max na plasma - 24 ng / ml na 47 ng / ml, n'otu n'otu.

Na oge nkezi nke T ikpeazụ_1/2 saxagliptin na metabolite ya bụ isi bụ elekere abụọ na ọkara na awa 3.1, n'otu n'otu, yana ọnụ ahịa mgbochi nke T_1/2 Plasma DPP-4 - awa 26,9 9. Mkpuchi Plasma DPP-4 ọrụ opekata mpe awa 24 ka nchịkwa nke saxagliptin bụ n'ihi ịdị elu ya dị elu maka DPP-4 na ogologo oge na-ejikọ ya. Achọpụtaghị nnukwu ihe mejupụtara ọgwụ zirigliptin na metabolite ya na iji ọgwụ ogologo oge oge 1 ụbọchị. Enweghi ihe ndabere nke nhicha nke saxagliptin na metabolite ya kachasị na usoro ọgwụ na oge ọgwụgwọ mgbe ị na-ewere saxagliptin 1 oge / ụbọchị na usoro onunu si 2.5 mg ruo 400 mg maka ụbọchị 14.

Mgbe nchịkwa ọnụ gasịrị, ọ dịkarịa ala 75% nke dose nke saxagliptin na-abanye. Iri nri emetụtaghi ọgwụ pharmokokinetics nke saxagliptin na ndị ọrụ afọ ofufo ahụ siri ike. Nri nwere nnukwu abuba emetughi C_max saxagliptin, ebe AUC mụbara site na 27% jiri ya na-ebu ọnụ. Oge iru C_max maka saxagliptin mụbara ihe dịka awa 0,5 mgbe ị na-a theụ ọgwụ ahụ nri site na iji ọnụ. Agbanyeghị, mgbanwe ndị a adịchaghị mkpa n'ịgwọ ọrịa.

Njikọ nke saxagliptin na metabolite ya na protein protein n'ọbara abụghị ihe dị mkpa; yabụ, enwere ike iche na nkesa nke saxagliptin na mgbanwe na protein protein nke ọbara ọbara hụrụ na hepatic ma ọ bụ akụrụ agaghị enwe nnukwu mgbanwe.

Saxagliptin bụ metabolized tumadi na ntinye nke isoenzymes nke cytochrome P450 3A4 / 5 (CYP 3A4 / 5) na nguzobe nke metabolite dị ike, mmetụta inhibitory nke megidere DPP-4 bụ ugboro abụọ adịghị ike karịa nke saxagliptin.

Saxagliptin dị na mmamịrị na bile. Mgbe otu ọgwụ were 50 mg nke akara 14 C-saxagliptin, akụrụ 24% nke ọgwụ ahụ ka aminagliptin na-agbanweghi agbanwe agbanwe yana 36% bụ metabolite nke saxagliptin. Ngụkọta akwara ozi hụrụ na mmamịrị ruru 75% nke ọgwụ a .ụrụ.Nkezi mkpocha ezigharịrị nke saxagliptin dị ihe dị ka 230 ml / min, uru gbachapụrụ agbacha gbacha gbacha gbata ruru 120 ml / min. Maka isi metabolite, mkpochapu akụrụ bụ ihe pụtara na uru nke ikpocha ụwa.

Ihe dị ka pacenti 22% nke ikuku redio a hụrụ na feces.

Pharmacokinetics n'ihe gbasara ọrịa

N'ime ndị ọrịa nwere ezughi oke gbasara akụrụ, ụkpụrụ nke AUC nke saxagliptin na metabolite ya kachasị elu bụ 1.2 na 1.7 karịa, n'otu n'otu, karịa ndị mmadụ nwere ọrụ gbasara ọrụ nkịtị. Mmụba a na ụkpụrụ AUC abụghị ihe dị mkpa gbasara ụlọ ọgwụ, ya mere, ọ chọghị ịmegharị dose.

N'ime ndị ọrịa nwere ezughi oke gbasara akụrụ, yana ndị ọrịa nwere hemodialysis, ụkpụrụ nke AUC nke saxagliptin na metabolite ya kachasị elu bụ 2.1 na oge 4.5 dị elu, karịa, ndị ahụ n'otu n'otu nwere ọrụ gbasara ọrụ nkịtị. Maka ndị ọrịa nwere obere akụrụngwa arụ ọrụ, yana ndị ọrịa na hemodialysis, mkpụrụ nke saxagliptin kwesịrị ịbụ 2.5 mg 1 oge / ụbọchị.

N'ime ndị ọrịa nwere ọria nkwarụ dị nro, na-agafe agafe, ọ nweghị mgbanwe dị egwu na ọgwụ ọgwụ nke saxagliptin, ya mere, a chọghị ịgbanwe mgbanwe maka ndị ọrịa dị otú ahụ.

N'ime ndị ọrịa dị afọ 65-80, enweghị ọdịiche pụtara ìhè dị na pharmacokinetics nke saxagliptin ma e jiri ya tụnyere ndị ọrịa dị obere (afọ 18-40), yabụ, achọrọ nhazigharị ọgwụgwọ na ndị ọrịa agadi. Agbanyeghị, ekwesịrị iburu n'uche na n'ụdị ndị ọrịa a, mbelata ọrụ akụrụ nwere ike ịdị.

Elldị shuga mellitus 2 na mgbakwunye na nri na mmega iji melite njikwa glycemic na ogo:

- na - amalite usoro ọgwụgwọ na metformin,

- agbakwunye na monotherapy nwere metformin, thiazolidinediones, usoro nke sulfonylurea, na enweghị enweghị nchịkwa glycemic zuru oke na usoro ọgwụgwọ a.

- ụdị shuga mellitus nke 1 (adịghị amụ amụ),

- iji insulin eme ihe (adighi amu ya),